白蛋白市場規模、佔有率和成長分析（按類型、應用、銷售管道、最終用戶和地區）- 2025-2032 年產業預測

2023 年白蛋白市場規模價值為 66.9 億美元，預計將從 2024 年的 70.8 億美元成長到 2032 年的 112.1 億美元，預測期內（2025-2032 年）的複合年成長率為 5.9%。

全球白蛋白市場預計將顯著成長，因為它具有增加血液容量、治療肝病和治療燒燙傷等重要的醫療應用。白蛋白的主要功能是維持滲透壓和運輸必需物質，增強了其治療潛力。促進因素包括危及生命的疾病盛行率上升、外科手術數量增加（2022 年全球將進行 3.1 億例手術）以及非治療用途的增加。 Grifols 對熊果素治療肝硬化的評估，以及 Shilpa Biologicals 的環境友善重組人體血清蛋白等創新進展標誌著人們正向更有效、更永續的產品轉變。 AlvMedics 和 Valneva 等公司在改進疫苗配方方面的合作表明了該行業對推進醫療保健解決方案和增加全球獲得基本治療機會的承諾。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

白蛋白市場規模（按類型）

• 市場概況
• 人血清白蛋白
• 牛血清白蛋白
• 重組白蛋白

白蛋白市場規模（按應用）

• 市場概況
• 治療
• 藥物處方和疫苗
• 媒體元件
• 其他用途

白蛋白市場規模（依銷售管道）

• 市場概況
• 企業對消費者 (B2C)
• 企業對企業 (B2B)

白蛋白市場規模（依最終用戶分類）

• 市場概況
• 醫院和診所
• 製藥和生物技術公司
• 研究組織

白蛋白市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Merck KGaA（Germany）
• CSL Limited（Australia）
• Grifols SA（Spain）
• Baxter International Inc.（USA）
• China Biologic Products Holdings, Inc.（China）
• Takeda Pharmaceuticals（Japan）
• Octapharma AG（Switzerland）
• Novozymes A/S（Denmark）
• Thermo Fisher Scientific Inc.（USA）
• Ventria Bioscience（USA）
• Albumedix Ltd.（UK）
• Biotest AG（Germany）
• HiMedia Laboratories（India）
• Invitria（USA）
• Medxbio Pte Ltd.（Singapore）
• RayBiotech, Inc.（USA）
• SeraCare（USA）
• Kedrion SpA（Italy）
• Albumin Therapeutics, LLC（USA）

結論和建議

Albumin Market size was valued at USD 6.69 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 11.21 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The global albumin market is poised for significant growth due to its critical medical applications in increasing blood volume, treating liver diseases, and managing burn injuries. Key functions of albumin, such as maintaining osmotic pressure and transporting essential substances, enhance its therapeutic potential. Driving factors include the rising prevalence of life-threatening diseases, an increase in surgical procedures-310 million surgeries were performed globally in 2022-and an uptick in non-therapeutic uses. Innovative advancements, like Grifols' evaluation of Albutein for cirrhosis, and Shilpa Biologicals' environmentally friendly recombinant Human Albumin, signal a shift towards more effective and sustainable products. Collaborations, like that of Albumedix with Valneva to improve vaccine formulations, represent the industry's commitment to advancing healthcare solutions and boosting global access to essential treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Albumin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Albumin Market Segments Analysis

Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Albumin Market

The albumin market is driven by several key factors, notably the rising demand for albumin in regenerative medicine, vaccine stabilization, and drug formulations. Its significance in contemporary biopharmaceuticals is highlighted by its applications in plasma expansion, drug delivery systems, and nanomedicine. Additionally, the increasing prevalence of chronic diseases, including conditions such as hypovolemia and liver disorders, is prompting pharmaceutical companies to innovate and develop new therapeutic drugs. This growing patient population necessitates advanced treatments, further stimulating the demand for albumin and enhancing its role as a crucial component in various medical applications and drug formulations.

Restraints in the Albumin Market

The albumin market faces significant challenges due to the intricate and costly production processes, particularly for recombinant albumin. The extensive reliance on plasma collection results in complexities surrounding purification and quality control for plasma-derived albumin. Additionally, the operational costs are heightened by fluctuations in plasma supply, stringent regulatory approval processes, and the necessity for cold-chain logistics. These factors collectively impede accessibility and affordability, particularly in developing regions, ultimately acting as major restraints on the albumin market's growth and expansion potential, affecting both manufacturers and end-users alike.

Market Trends of the Albumin Market

The albumin market is experiencing a notable shift towards sustainable production methods, with a growing emphasis on recombinant albumin. Concerns surrounding plasma sourcing, potential pathogen transmission, and supply chain vulnerabilities are driving companies to invest in genetic engineering technologies. This transition is yielding innovative alternatives, including plant-based and yeast-expressed recombinant albumin, which promise enhanced safety and environmental sustainability. As the industry pivots away from traditional plasma-derived products, these advancements not only address contamination risks but also offer cost-effective solutions that appeal to both manufacturers and consumers. This trend underscores a broader commitment to safety and sustainability in biopharmaceutical manufacturing.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Albumin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Human Serum Albumin
• Bovine Serum Albumin
• Recombinant Albumin

Global Albumin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Drug Formulation and Vaccines
• Component of Media
• Other Applications

Global Albumin Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Business-To-Consumer (B2C)
• Business-To-Business (B2B)

Global Albumin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutes

Global Albumin Market Size & CAGR (2025-2032)

• North America (Type, Application, Sales Channel, End-User)
  • US
  • Canada
• Europe (Type, Application, Sales Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Sales Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Sales Channel, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Sales Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novozymes A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ventria Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumedix Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HiMedia Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitria (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medxbio Pte Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayBiotech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SeraCare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albumin Therapeutics, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations